Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Bocanegra

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
International Journal of Molecular Sciences|June 28, 2023
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung CancerHugo Arasanz, Luisa Chocarro, Leticia Fernández-Rubio, et al.
Frontiers in Pharmacology|April 23, 2020
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?Luisa Chocarro de Erauso, Miren Zuazo, Hugo Arasanz, et al.
International Journal of Molecular Sciences|June 2, 2021
Understanding LAG-3 SignalingLuisa Chocarro, Ester Blanco, Miren Zuazo, et al.
Transfusion|January 8, 2025
A paired study comparing mononuclear cell collection using a new in-line system with an off-line extracorporeal photopheresis apheresis systemSilvia Monsalvo, Claudia Quintana, Claudia Mosquera, et al.
Cancers|February 9, 2020
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell DynamicsHugo Arasanz, Miren Zuazo, Ana Bocanegra, et al.
Cancers|August 9, 2020
Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT InhibitionHugo Arasanz, Carlos Hernández, Ana Bocanegra, et al.
International Journal of Molecular Sciences|April 30, 2021
Hyperprogressive Disease: Main Features and Key ControversiesHugo Arasanz, Miren Zuazo, Ana Bocanegra, et al.
EMBO Molecular Medicine|July 6, 2019
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapyMiren Zuazo, Hugo Arasanz, Gonzalo Fernández-Hinojal, et al.
British Journal of Cancer|January 10, 2024
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategiesEster Blanco, Noelia Silva-Pilipich, Ana Bocanegra, et al.
Life (Basel, Switzerland)|April 23, 2022
CAR-T Cells for the Treatment of Lung CancerLuisa Chocarro, Hugo Arasanz, Leticia Fernández-Rubio, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
International Journal of Molecular Sciences|June 28, 2023
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung CancerHugo Arasanz, Luisa Chocarro, Leticia Fernández-Rubio, et al.
Frontiers in Pharmacology|April 23, 2020
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?Luisa Chocarro de Erauso, Miren Zuazo, Hugo Arasanz, et al.
International Journal of Molecular Sciences|June 2, 2021
Understanding LAG-3 SignalingLuisa Chocarro, Ester Blanco, Miren Zuazo, et al.
Transfusion|January 8, 2025
A paired study comparing mononuclear cell collection using a new in-line system with an off-line extracorporeal photopheresis apheresis systemSilvia Monsalvo, Claudia Quintana, Claudia Mosquera, et al.
Cancers|February 9, 2020
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell DynamicsHugo Arasanz, Miren Zuazo, Ana Bocanegra, et al.
Cancers|August 9, 2020
Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT InhibitionHugo Arasanz, Carlos Hernández, Ana Bocanegra, et al.
International Journal of Molecular Sciences|April 30, 2021
Hyperprogressive Disease: Main Features and Key ControversiesHugo Arasanz, Miren Zuazo, Ana Bocanegra, et al.
EMBO Molecular Medicine|July 6, 2019
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapyMiren Zuazo, Hugo Arasanz, Gonzalo Fernández-Hinojal, et al.
British Journal of Cancer|January 10, 2024
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategiesEster Blanco, Noelia Silva-Pilipich, Ana Bocanegra, et al.
Life (Basel, Switzerland)|April 23, 2022
CAR-T Cells for the Treatment of Lung CancerLuisa Chocarro, Hugo Arasanz, Leticia Fernández-Rubio, et al.
Pageof 4